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Abstract: Parkinson's disease (PD) is the second leading age-related degenerative brain disease in the world affecting 
millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous 
emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly 
people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology 
and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at 
present no cure for it. Furthermore, there are no proven therapies for prevention of PD and although evidence exists of 
risk and protective factors, this is not strong enough to warrant specific measures in an attempt to diminish risk or enhance 
protection. Drug development programmes are engaged in finding neuroprotective and neurorestorative therapies or, even 
better, discovering drugs able to rejuvenate the dopaminergic neurons. The latest developments in this promising field 
will be discussed with reference to the current literature together with the advantages and pitfalls of suggested drugs. Fi-
nally, an analysis of the role of various dietary recommendations, lifestyle, environmental and other factors in reducing 
the risk of PD is carried out. 
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INTRODUCTION 
 Parkinson’s disease (PD) is the second most common 
neurodegenerative disease in the elderly population with an 
inevitable exitus. The idiopathic form is a progressive disor-
der the impact of which reaches far beyond the clinical signs 
and symptoms exhibited by those afflicted. This neurode-
generative disorder not only places a severe burden on the 
patients but also on their family, friends and society. 
 It is estimated that close to 4 million people worldwide 
suffer from PD. The disease afflicts both sexes, and the ini-
tial symptoms typically appear when people are in their late 
50’s or early 60’s. Indeed, nearly 1% of the population over 
the age of 65 is estimated to suffer from the disease. Moreo-
ver, the number of PD sufferers is expected to grow as the 
general population in the Western world ages. In fact, it has 
been estimated that this number will double to between 8.7 
and 9.3 million by 2030 [1]. Accordingly, the costs of treat-
ment (health and social care), estimated at between £560,000 
and £1.6 million per 100,000 population, is expected to rise 
sharply [2-4]. 
 Clinical features at presentation include the asymmetric 
onset of cardinal motor symptoms such as tremor at rest, 
bradykinesia, muscular rigidity, stooped posture and instabil-
ity [5]. These are the result of the loss of dopaminergic 
(DAergic) neurons in the substantia nigra pars compacta  
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(SNc), which causes a consequent reduction of dopamine 
(DA) levels in the striatum [6-8] and changes in the basal 
ganglia-thalamocortical network activity [9]. Regrettably, the 
symptoms of PD do not appear until up to 80% of the DAer-
gic nerve cells have been lost [10-11]. In the early stages of 
the disease, DA replacement therapy, using the DA precursor 
levodopa, is effective but the dose response decreases with 
disease progression and motor complications (dyskinesias) 
and other side effects (e.g. mood disorders, sleep distur-
bances) arise after chronic treatment. These complications 
may be due either to the advanced stage of the disease when 
degenerating DAergic neurons cannot buffer the fluctuating 
plasma levels of levodopa, resulting in pulsatile stimulation 
of the DA receptors, or to the further degeneration in non-
DAergic regions [12-13]. Since the underlying mechanisms 
of neuronal loss in patients are not known, current therapies 
work mainly to alleviate symptoms rather than to halt the 
progression of the disease [14]. 
 There have been major advances in understanding the 
etiopathogenesis of PD, the modalities whereby the neurode-
generative process begins and progresses (Fig. 1), therefore 
the development of drugs to slow and halt DAergic neuronal 
degeneration or even to prevent the disease, now seem realis-
tic goals. 
 This new optimism that PD can be defeated is tempered 
by the realization that we have not yet cured any neurode-
generative disorder, and defeating PD will require new dis-
coveries that cannot now be predicted with certainty. This is 
complicated by the large number of factors that seem to be 
involved in the onset of this disease, such as aging, genetic 
vulnerability, exogenous or endogenous toxins, hydroxyl 
radicals (
.
OH) production, neuronal metabolic disturbances, 
inflammation and apoptosis [5,15-21]. 
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Nigral Dopaminergic Neurons 
 Dopamine is one of the most intensively studied neuro-
transmitters in the brain due to its involvement in several 
mental and neurological disorders, such as schizophrenia, 
depression and PD. The SNc resides in the ventral part of 
mesencephalon, laterally to the ventral tegmental area of 
Tsai (VTA), the other major DAergic nucleus in the central 
nervous system (CNS) [22-26]. The majority (>90%) of cells 
in the SNc are medium sized aspiny DAergic neurons with 
sparsely branching dendritic trees. These neurons’ preferred 
pathway is to the caudate nucleus and the putamen, i.e. the 
dorsal part of the striatum, and therefore this pathway is of-
ten called the nigrostriatal DAergic system [27]. According 
to their neurotransmitter, nigral neurons are classified into 
DAergic and -aminobutyric acid (GABA)-ergic neurons 
[28-30]. 
 From an electrophysiological point of view, DAergic 
neurons in the SNc can be further distinguished from other 
neuronal populations in the brain on the basis of intrinsic 
membrane properties that allow them to discharge in vivo 
spontaneously, in a spectrum of patterns ranging from pace-
maker, to random and bursting modes [31-34]. These firing 
patterns, which are controlled by a complex interplay of ion 
or receptor channels [35,36], allow DA neurons to optimize 
the release of DA in their terminal fields [37]. However. the 
peculiarity of SNc DA neurons is that they are spontaneously 
active even in vitro without synaptic input. Such autonomous 
'pacemaking' activity is seen in many types of neurons and 
requires ion channels that can open at membrane potentials 
lower than the threshold for firing action potentials. Pace-
maker activity seems to be critical to the function of SNc 
DAergic neurons by maintaining DA levels in target struc-
tures like the striatum. Also, emerging evidence indicates 
that electrical activity might participate in the control of 
DAergic neuron survival, not only during development, but 
also in the adult brain, thus raising the possibility that altera-
tions in ionic currents could contribute actively to the demise 
of these neurons in PD [38]. The electrical current entering 
the cell through these channels then depolarizes the mem-
brane to the threshold for action potentials. Differently from 
other pacemaking neurons where sodium ions are involved, 
the driving pacemaking current in the DAergic neurons in 
adult animals is carried mainly by calcium ions (Ca
2+
) 
through the low-voltage-activated neuronal L-type Ca
2+
 
channels (VGCC) with the  subunit Cav1.3 [39-41]. Strik-
ingly, in juvenile SNc DAergic neurons, pacemaking is 
driven by sodium channels in conjunction with hyperpolari-
zation-activated cyclic nucleotide-gated cation (HCN) chan-
nels. Thereafter, there is a gradual switch as Cav1.3 current 
increases, during the second week following birth, perhaps 
as the voltage dependence of HCN channels is shifted to-
ward more negative membrane potentials, essentially inacti-
vating HCN channels [41]. The development of SNc Ca
2+
-
driven pacemaking occurs in tandem with an increased ex-
pression of slowly inactivating somatodendritic L-type Ca
2+
 
channels that drive the neurons into oscillations, due to the 
presence of Cav1.3  subunits, which open in a relatively 
hyperpolarized subthreshold range. In support of these new 
observations, knockout mice that do not express the Cav1.3  
subunit of L-type Ca
2+
 channels continue to show SNc 
pacemaking driven by the sodium/HCN currents throughout 
their lives. In this respect, SNc DAergic neurons of knockout 
mice also resembled juvenile SNc DAergic neurons. The 
mechanisms underlying the shift from juvenile and adult 
pacemaking are not known yet. Nevertheless, it seems plau-
sible that cyclic adenosine monophosphate (cAMP) and 
Ca
2+
-inhibited isoforms of the enzyme that produces cAMP 
are involved. When the Ca
2+
 cytoplasmic concentration 
drops due to the absence of expression of Cav1.3 channels 
the cAMP concentration increases inside the DA neuron. 
Consequently the HCN channels that are regulated by cAMP 
in a positive positive allosteric manner, drive the pacemak-
ing activity [41]. 
Calcium Channel Blockers: Rejuvenating Agents? 
 DAergic neurons seem to be particularly prone to dying 
owing to their peculiar characteristics such as high iron lev-
els, low glutathione concentration and high presence of reac-
tive glia [42]. These neurons are further stressed via their 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A simplified diagram showing the interaction of different factors leading to nigral cell damage and death. 
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pacemaking activity which leads to an intracellular Ca
2+
 ac-
cumulation and might unsettle the ion cellular homeostasis. 
This phenomenon, in predisposed individuals, can cause the 
death of DAergic neurons. Ca
2+
 can kill DA neurons by dif-
ferent mechanisms. Ca
2+
 activates cysteine proteases called 
calpains and caspases triggering apoptotic cascades. In addi-
tion, Ca
2+
 induces oxidative stress through several different 
mechanisms, including activation of oxygenases, perturba-
tion of mitochondrial Ca
2+
 and energy metabolism, and in-
duction of membrane associated oxidative stress (MAOS). In 
consequence, there is an intracellular accumulation of reac-
tive oxygen species (ROS) such as superoxide anion radical, 
hydrogen peroxide, hydroxyl radical, nitric oxide (NO) and 
peroxynitrite [43,44]. In line with these findings, it has been 
suggested that Ca
2+
 channel blockers (CCBs), such as ni-
modipine and other dihydropyridine drugs (Fig. 2), might be 
useful to heal neuronal death resulting from excessive 
Ca
2+
entry [44]. This hypothesis is corroborated by the evi-
dence that DAergic neurons expressing relatively high levels 
of the Ca
2+
-binding proteins calbindin and calretinin appear 
to be resistant to degeneration in PD [45,46]. CCBs may 
inhibit the Ca
2+
-dependent process of apoptosis [47] and be 
neuroprotective in PD and other conditions in which apopto-
sis contributes substantially to cell death [48]. Furthermore, 
some epidemiologic studies have revealed a significant de-
creased risk of PD associated with hypertension and blood 
pressure medication [49,50]. In animal models of PD, ni-
modipine prevented neurotoxicity induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) in non-human 
primates [51], mice [52], and in cerebellar granule cells [53] 
but unexpectedly not in rats [54]. In common marmosets and 
mice, pretreatment with nimodipine completely prevented 
(in a dose-dependent manner) the MPTP-induced decrease of 
nigral tyrosine hydroxylase (TH) immunoreactive cells, but 
neither attenuated the behavioural impairments in MPTP-
treated animals nor antagonized the striatal neurotoxin-
induced DA depletion. These data suggest that nimodipine 
might protect at the cellular nigral level, but not at the synap-
tic striatal level, implicating differential mechanisms of the 
actions of MPTP-induced neurotoxicity at the nigral versus 
the striatal level [51,52]. Recently, it has been shown that 
isradipine (Fig. 2), another CCB drug of the dihydropyridine 
class, may have potential uses for treating and preventing PD 
[41]. Its neuroprotective action is linked to the block of the 
Ca
2+
current underlying pacemaking in SNc neurons, inter-
rupting the ion accumulation. The treatment with isradipine 
switches the pacemaker activity of SNc neurons from Cav1.3 
channels to the immature pacemaking driven by HCN chan-
nels. Theoretically, the drug rejuvenates aged SNc neurons 
into a state in which they are more resistant to oxidative 
stress. This hypothesis is confirmed by the evidence that the 
pesticide rotenone in vitro has a far less damaging effect on 
SNc DAergic neurons in Cav1.3-deficient mice than in wild 
mice, and that the damage can be reduced by isradipine. 
Moreover, in a mouse model of PD produced by MPTP in-
jection, isradipine administered in vivo reduces both the loss 
of SNc neurons and the development of movement disorders. 
There is hope that the drug will protect DA neurons in hu-
mans as well, so that if taken early enough by those at high 
risk of PD, it will prevent the disease. Isradipine could be 
taken in much the same way as aspirin is taken to protect the 
heart and might also significantly benefit people who already 
have PD [41]. The fact that the ‘rejuvenation’ can be brought 
about by treatment with isradipine, a very well-tolerated 
drug that is widely used in the treatment of hypertension and 
stroke, points to a neuroprotective strategy that could be tried 
immediately. These are exciting results, because nimodipine 
is a well studied drug with relatively mild side effects. How-
ever, there are some caveats. It is uncertain whether the ‘re-
juvenated’ pacemaking in nimodipine-treated SNc neurons 
leads to adequate DA release, especially from dendrites. 
Moreover, the nimodipine concentrations used in the in vitro 
studies by Chan et al. [41] were far higher than the plasma 
concentrations of this drug that occur in its clinical use for 
treating high blood pressure, and thus might produce more 
severe side effects than are so far known. A further note of 
caution is struck from the observation that mice that lack the 
Cav1.3 subunit are deaf [55], as might be expected from the 
abovementioned roles of L-type Ca
2+
 channels in cochlear 
hair cell activity. Finally, L-type channels further appear to 
underlie forms of synaptic plasticity, and CCBs may inter-
fere with these normal synaptic functions. In line with these 
experimental findings, a retrospective study of hypertensive 
patients suggested that dihydropyridine use might lower the 
incidence of PD by 30-50% [48]. Diminishing the vulner-
ability of SNc DAergic neurons should not only decrease the 
incidence of PD but also slow its progression, broadening the 
therapeutic window for PD patients in the early stages of the 
disease. Preliminary population studies have been performed 
to date, suggesting that CCBs use may be less common in 
hypertensive PD patients than in non-PD hypertensive pa-
tients. However, the enthusiasm for a rationale for the use of 
CCBs in PD has been dampened by a recent population-
based case-control study [56] in which the risk of PD associ-
ated with CCBs and beta-blockers was undertaken. No asso-
ciation with PD risk for either class of medication in terms of 
duration, dose, number of prescriptions or pattern of use was 
observed. The weakness of these associations and the ab-
sence of the additional influence of dose or duration of use 
argue against any causal interpretation [56]. More extensive 
investigations of this type and prospective studies of Ca
2+
 
antagonist use in PD will be required to determine if these 
agents truly have a salutary effect on Parkinsonism. Never-
theless, CCBs neuroprotective therapy should begin well 
before the appearance of symptoms, at a stage where altering 
the rate of cell loss can have the greatest effect on the timing 
of the threshold crossing and the emergence of symptoms. 
Lipid-Lowering Drugs in PD? 
 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors or statins are the most successful 
cardiovascular drugs of all time. By interrupting cholesterol 
synthesis in the liver, they activate hepatocyte low-density 
lipoprotein (LDL) receptors and produce consistent and pre-
dictable reductions in circulating LDL cholesterol (LDL-C) 
with resulting reproducible improvements in cardiovascular 
risk by retarding or even reversing the progression of athero-
sclerosis in all major arterial trees [57]. As such, statins are 
amongst the most extensively investigated pharmaceutical 
agents in current clinical use [57]. 
 Interestingly, a number of recent studies indicate that 
apart from their lipid-lowering activities, statins and fibrates 
(Fig. 2) (the latter activate instead the peroxisome prolifera-
tor-activated receptors (PPAR)), exhibit multiple functions 
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and serve to modulate intracellular signalling pathways, in-
hibit inflammation, suppress the production of reactive oxy-
gen species, and modulate T cell activity. Therefore, these 
drugs are now being considered as possible therapeutics for 
several forms of human disorders including PD and Alz-
heimer disease (AD) [58]. 
 Strong evidence has supported a rationale for the use of 
statins in AD [59] since the polymorpholism of genes of 
apolipoprotein (APOE) 4 consistently associated with 
higher plasma LDL-C is associated with the frequency of 
AD development [60,61]. A positive correlation between a 
high serum cholesterol level and risk factor for AD has been 
shown, and treatment with statins reduces the frequency of 
AD development [59]. 
 Cholesterol and fat levels seem to be involved in PD 
pathophysiology as well. Nevertheless, the association be-
tween fat intakes and risk of PD is less clear than in AD and 
contradictory epidemiological findings have been reported 
[62,63]. Recent results do not support the importance of 
overall fat intake in the pathogenesis of PD, but a possible 
adverse effect of saturated fat for men could not be excluded. 
Conversely, high intake of unsaturated fatty acids might in-
stead protect against PD [64,65]. However, a recent system-
atic review, demonstrated that APOE 2 allele, associated 
with lower plasma LDL-C, is positively associated with 
higher prevalence of sporadic PD, suggesting that LDL-C 
levels are associated with PD [66]. In effect, Huang et al. 
[67] reported that lower serum concentrations of LDL-C 
were associated with a higher prevalence of PD, whereas use 
of cholesterol-lowering drugs was significantly associated 
with a decreased occurrence of PD. Therefore, either an etio-
logic role of LDL-C in PD pathogenesis or a neuroprotective 
effect of statins has been suggested [67]. This association 
was found in both men and women and persisted after fur-
ther adjusting for LDL-C concentration. Although these ob-
servations were made in a relatively small, retrospective 
case-control study, they have been confirmed by a recent 
publication from the Rotterdam Study group [68]. In this 
study a significant association was revealed between higher 
levels of total serum cholesterol and a decreased risk of PD, 
with analyses in quintiles showing a clear linear relation. 
Surprisingly, the cholesterol protection was restricted to 
women and the association between statin use and risk of 
incident PD was not significant, although the trend was posi-
tive. The high serum cholesterol neuroprotective effect can 
be related to the consequent high levels of coenzyme Q10 
(CoQ 10) transported by LDL-cholesterol. CoQ 10 is essen-
tially a vitamin or vitamin-like substance with a powerful 
antioxidant activity and electron acceptor for mitochondrial 
complex I [69]. Given the hypothesis that oxidative stress 
and mitochondrial complex I dysfunction play a central role 
in the pathogenesis of PD, CoQ 10 is considered a candidate 
drug for treatment of PD and has already been investigated 
in small trials [70,71]. However, further research is needed 
to unravel the association between cholesterol, CoQ 10, and 
PD pathogenesis. 
 The neuroprotective effects of statins has not been con-
firmed by Kreisler and colleagues [72] but revealed in another 
larger study [73]. In this study, using a population of 4.5 mil-
lion people, subjects taking simvastatin were associated with a 
49% decrease in incidence of PD. Not all statins were equal; 
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Fig. (2). (1) Nimopidine, O5-(2-methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. (2) 
Isradipine, O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate. (3) Simvastatin, 
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbut-
anoate. (4) Lovastatin, [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-
1-yl] (2S)-2-methylbutanoate. (5) atorvastatin, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-
dihydroxyheptanoic acid. (6) Fenofibrate, propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate. 
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indeed, lovastatin, and atorvastatin were not associated with a 
reduction in the number of cases of PD [73]. The different 
effect of statins might derive from their diverse biological 
actions, such as effectiveness at modifying lipid metabolism, 
ability to penetrate the blood-brain barrier and other independ-
ent effects from the hypolipidemic actions [74]. 
 The importance of non hypocholesterolemic properties of 
statins in protecting DAergic neurons was suggested for the 
first time by Obata and Yamanaka [75]. In fact, it has been 
shown that fluvastatin decreased formation of 
.
OH induced 
by the MPP
+
 probably blocking LDL oxidation [75], simvas-
tatin inhibited the activated microglia thereby iinhibiting the 
production of tumor necrosis factor (TNF)-, nitric oxide, 
and superoxide without affecting cholesterol concentrations 
in the plasma or in the striatum [76]. In addition, lovastatin 
reduced -synuclein (-syn) accumulation and aggregation 
[77]. 
 Nevertheless, Kreisler et al. [72], showed that atorvas-
tatin and simvastatin instead had a deleterious effect on the 
number of TH-positive cells in MPTP-lesioned mice. The 
evidence is not surprising considering that statin toxicity has 
been observed not only in myocytes but also in other cell 
types, due to some oncotic and apoptotic mechanisms [78] or 
proteasome inhibition [79]. 
 Another member of the lipid-lowering drugs, fenofibrate, 
has shown to have a protective effect against the toxic effect 
of MPTP in animals in vivo [72]. Fibrates are synthetic 
ligands for PPAR-. This receptor is expressed in various 
tissues, including CNS neurons and astrocytes in the rat SNc 
and striatum [72,80,81]. PPAR- is activated by natural 
ligands (such as fatty acids and their derivatives), and modu-
lates the transcription of a large number of target genes via 
formation of heterodimeric transcription factor complexes 
with the retinoid X receptor. PPAR- probably modulates 
oxidative stress [82] activating the major antioxidant en-
zymes in the brain [83], reduces the production of inflamma-
tory cytokines, such as the TNF-, interleukin-6 (IL-6), and 
inhibits pro-inflammatory proteins such as nuclear factor-
kappa B (NF-B), inducible NO synthase (iNOS), cyclooxy-
genase-2 (COX-2), vascular cell adhesion molecule-1 and 
intracellular adhesion molecule-1 [84]. Hence, PPAR- acti-
vation appears to be an interesting pharmacological target in 
preventing or slowing PD. 
 Noticeably, the synthetic activation of PPAR- by fen-
ofibrates increases the number of DAergic neurons in the 
control animals, likely inducing cell differentiation [84]. 
 Overall, although not all consistent, these results indicate 
that lipid-lowering drugs might be useful in prevention of 
PD; particularly in secondary prevention once subjects at 
risk of developing PD have been identified. Indeed, after the 
disease onset their use may no longer be beneficial, as Lie-
berman and colleagues [85] have reported. They did not find 
any difference in the statin versus no statin group of PD pa-
tients for dementia, dyskinesia and wearing-off rates. Anec-
dotally, five patients reported a worsening of PD within 1-3 
months of starting a statin [85]. 
Aspirin in PD Prevention? 
 Recently, the involvement of inflammation and micro-
glial activation in the pathogenesis of PD has been empha-
sized [42,86]. The brain had been considered an immune 
privileged site, free from immune reactions, since it is pro-
tected by the blood-brain-barrier. However, accumulating 
findings have revealed that immune responses may occur in 
the brain, especially due to activation of the microglia. The 
inflammatory process is now thought to be fundamental to, if 
not at first the initiator of, the progression of PD pathogene-
sis. Results of neurotoxin models of PD, corroborating find-
ings obtained in transgenic animal models and epidemiologi-
cal studies, strongly support the hypothesis that this neu-
rodegenerative disease is not purely neuronal, as has been 
previously considered [87,88]. Thus, DAergic neuronal de-
generation is the likely result of multiple pathogenic factors 
occurring both within and outside the cell. 
 Moreover, neuroinflammation may aggravate the course 
of the disease and, as has recently been suggested, may
 
be a 
primary factor in some cases of PD [86,88]. In fact, postmor-
tem examinations have shown that neuronal degeneration in 
PD is associated with massive gliosis due to a subset of acti-
vated glial cells, the microglia [89], evidence that has been 
confirmed in MPTP-induced parkinsonism in monkeys [87]. 
Interestingly, healthy SNc exhibits the highest concentration 
of microglia in the brain especially in the ventral tier of the 
pars compacta [90]. Glial cells once activated become 
phagocytes and ingest degenerating DA neurons piece-by-
piece [91]. In addition, activated glial cells release detrimen-
tal compounds such as, interleukin-1 (IL-1), IL-6, TNF- 
and interferon  (IFN- ), which may act by stimulating 
iNOS, or which may exert a more direct deleterious effect on 
DAergic neurons by activating receptors that contain intracy-
toplasmic death domains involved in apoptosis [92]. In-
flammation has been rightly defined as a double-edged 
sword. It normally starts as a defence reaction, but the failure 
of its control mechanism can lead to an uncontrolled and 
continuous extremely damaging immune response. A brief 
pathogenic insult, furthermore, can induce an ongoing in-
flammatory response and the toxic substances released by 
the glial cells may be involved in the propagation and per-
petuation of neuronal degeneration. 
 From this evidence it appears clear that inflammatory 
process and oxidative stress derived from DA metabolism, 
constitute a vicious cycle that lead to the final demise of ni-
gral DA cells (Fig. 1) [88]. Furthermore, it has been demon-
strated that the COX-2 is up-regulated in SNc DAergic neu-
rons in both PD patients and animal models of PD [42]. 
 The above discussion makes it plausible that drugs with 
the capacity to rescue DA neurons from microglia toxicity 
and inflammatory processes may result in an amelioration of 
Parkinsonian symptoms by delaying the onset and slowing 
the progression of the disease and, strikingly, decreasing the 
risk of developing it. Therefore, aspirin and other nonsteroi-
dal anti-inflammatory drugs (NSAIDs) (Fig. 3) may repre-
sent a possible new therapeutic approach for treating PD and 
maybe for its prevention [42]. 
 NSAIDs are capable of halting eicosanoids synthesis and 
suspending inflammatory process progression. NSAIDs in-
hibit COX activity inducing a diminution of prostaglandins 
(PGs) levels, accompanied by a compensatory increase in 
levels of leucotrienes (LTs). Although some of the NSAIDs’ 
pharmacological actions are related to the ability to inhibit 
PG biosynthesis (classical effects), more of their beneficial 
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therapeutic effects are not and are also not completely under-
stood (non classical effects) [42]. Indeed, NSAIDs are able 
to inactivate the NF-B, factor activator protein 1 (AP-1) 
[93,94], inhibit the expression of some genes such as COX-
2, iNOS and IL-4 [95,96]. 
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Fig. (3). (7) Aspirin, 2-acetyloxybenzoic acid. (8) Ibuprofen, 2-[4-
(2-methylpropyl)phenyl]propanoic acid. (9) Naproxen, (2S)-2-(6-
methoxynaphthalen-2-yl)propanoic acid. (10) Indomethacin, 2-[1-
(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid. 
 In addition, it has been shown that NSAIDs in neuronal 
cells, might directly and dose-dependently scavenge ROS and 
reactive nitrogen species (RNS) blocking their detrimental 
effects [97]. Furthermore, some NSAIDs such as ibuprofen 
and indomethacin, show agonistic activity with the PPAR- 
[98]. Almost all the experimental findings in this field have 
consistently shown a neuroprotective effect of NSAIDs in 
different PD models both in vivo and in vitro. Differently, the 
mechanism whereby aspirin and the other NSAIDs act is still a 
matter of debate. Some experimental evidence suggests that 
their neuroprotective properties are essentially due to a non-
classical mechanism such as inhibition of NF-B [99], ROS 
scavenging activity [100,104], caspase activation [103] mito-
chondrial function restoration [105] or some COX-
independent effects not yet identified [106]. 
 On the other hand, numerous findings have instead empha-
sized the selective involvement of COX-2 inhibition in 
NSAIDs neuroprotective effects [107,111]. Pre-treatment with 
COX-2 inhibitors has constantly induced neuroprotection 
[111,112], supporting a possible role for them as prophylactic 
therapy for PD. Nevertheless, the selective COX-2 inhibitor 
indomethacin, did not show any neuroprotective effect when 
administered after toxin-induced nigral degeneration, reveal-
ing that the time of COX-2 inhibition is critical to achieve a 
protective effect [113]. Indeed, COX-2 activity, PGs produc-
tion and oxygen species formation might not play a detrimen-
tal role in neuronal cells’ death, at least when the injury proc-
ess has started already. Furthermore, in later stages of injury, 
COX-2, through the formation of cyclopentenone PGs derived 
from PG D2 (PGD2), may participate in the resolution of in-
flammation and even in the regeneration process. Conse-
quently, the inhibition of COX-2 activity could be harmful to 
neurons injured by toxins. This hypothesis is supported by the 
fact that neither pharmacological nor genetic abrogation of 
COX-2 activity mitigates inflammatory processes [107]. Dif-
ferently to COX-2 inhibitors, aspirin appears to offer an adju-
vant effect as well as the prophylactic one acting as a neuro-
protectant even after the toxin-induced nigral degeneration 
[114]. 
 Despite the evidence of inflammation in the brains of pa-
tients with PD, and in animal models of PD, NSAIDs have not 
yet been formally tested in PD. 
 The first epidemiological study in the subject showed a 
noteworthy evidence that regular users of aspirin have a sig-
nificantly lower risk (-45%) of PD than non-users [115]. 
These findings were partially confirmed in a successive study 
from the same group [116], in which only ibuprofen and not 
aspirin among all the NSAIDs was associated with a lower 
risk of PD. 
 Recently, a case-control study on subjects with no history 
of PD or parkinsonism-related drug use at baseline reported a 
surprising finding: non-aspirin NSAIDs use reduces PD risk in 
men but not in women. Use of non-aspirin NSAIDs was asso-
ciated with a 20% reduction in the incidence of PD among 
men, and a 20% increase in the incidence of PD among 
women [117]. Less promising insights have been provided by 
the last studies [56,118-120]. Bower and colleagues [118] 
found that cases of PD used NSAIDs (excluding aspirin) less 
frequently than controls; however, the difference did not reach 
significance. No significant association between PD and aspi-
rin, ibuprofen and naproxen in reducing the risk of PD was 
also observed in other population-based case-control studies 
[56, 118,119]. Therefore, the indications for a rationale for the 
use of NSAIDs for the prevention and treatment of PD are 
unclear and must be clarified and corroborated by clinical trial 
before any firm conclusions can be drawn. 
A Vaccine for Parkinson’s Disease? 
 As we have described in the previous paragraph, inflam-
mation increases the risk of PD and is now considered a hall-
mark of DAergic neuron demise [42,92]. Therefore, attenuat-
ing brain inflammation can affect the disease process. A pos-
sible strategy might be represented by adaptive immunity. 
Indeed, it has been shown that vaccination with CNS antigens 
expressed at the lesion site, can attenuate neuronal death 
[121]. Such self-antigen-stimulated T cells may retard neu-
ronal injury by producing neurotrophins or by influencing 
their production by local glial cells [122]. Consistent with this 
evidence, a recent report by Gendelman’s group [123] showed 
that therapeutic immunization protects DAergic neurons in a 
mouse model of PD. This is the first time that a vaccine strat-
egy has been used to confer neuroprotection for DAergic neu-
rons. The authors experimented with a drug called copolymer-
1 (Copaxone). Previous studies have shown that Copaxone, 
which is commonly used to treat multiple sclerosis (MS), in-
creases the number of immune T cells that secrete anti-
inflammatory cytokines and growth factors. Injection of im-
mune cells from mice that had received Copaxone immuniza-
tion into MPTP-treated mice was capable of significantly de-
creasing the degeneration of DAergic neurons. These mice 
also lost fewer DA nerve fibres than control mice and showed 
only a small decrease in the amount of DA in the striatum. T 
cells in the treated mice migrated to the damaged area of the 
brain, reduced the harmful reactions of the microglia, and trig-
gered a neuroprotective response. In addition, the vaccine 
dramatically increased the amount of glial-derived neurotro-
phic factor (GDNF), a growth factor that helps prevent neu-
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rodegeneration [123]. In addition, in a successive study 
Gendelman’s group further showed Copaxone immune cell 
protection of the nigrostriatal DAergic pathway in MPTP-
intoxicated mice using quantitative proton magnetic resonance 
spectroscopic imaging (
1
H MRSI) [124]. 
1
H MRSI performed 
in MPTP-intoxicated animals showed that Copaxone immuni-
zation strategies
 
counteract the decrease of N-acetylaspartate 
(NAA) levels seen in the control group, in the SNc and stria-
tum. What makes this research noteworthy is the new evi-
dence that DAergic degeneration can be evaluated by 
1
H 
MRSI which can serve as a monitoring system to assess thera-
peutic outcomes for PD. 
 These studies offer proof of the concept that the vaccina-
tion might modify the behaviour of the glial cells so that their 
responses are beneficial to the nervous system rather than 
harmful. In these studies adoptive transfer of Copaxone -
treated cells to MPTP recipient animals was necessary because 
the toxin immunotoxicity precluded active immunization. 
However, Copaxone could be given to humans directly. Fol-
low-up studies to confirm these results and to identify the spe-
cific cytokines, nerve growth factors, and other proteins that 
play a role in the protective response are warranted. Other 
work is needed to determine how to translate the study results 
into a therapy for humans and to make sure the treatment is 
safe for patients with PD, who may not react to the drug in the 
same way as MS patients. While Copaxone is currently ap-
proved by the U.S. Food and Drug Administration for use in 
treating MS, the dose needed to treat PD will probably be 
quite different from the dose used in treating MS. The timing 
of treatment may also prove critical. It is likely that this ther-
apy might eventually be able to slow the course of PD in hu-
mans. 
 A different immunotheraupetical approach to PD has been 
suggested by Masliah et al. [125]. The intended vaccine stimu-
lates the immune system to target the abnormal form of the 
protein -syn. Transgenic mice vaccinated with Human -syn 
(h-syn) presented a decreased accumulation of aggregated -
syn in neuronal cell bodies and synapses that was associated 
with reduced neurodegeneration. Furthermore, antibodies pro-
duced by immunized mice recognized abnormal -syn associ-
ated with the neuronal membrane and promoted the degrada-
tion of -syn aggregates, probably via lysosomal pathways. 
Similar effects were observed with an exogenously applied 
FITC-tagged -syn antibody. The antibodies produced by the 
vaccinated mice recognized and reduced only the abnormal 
form of -syn, since the protein's normal form is in a cellular 
compartment where antibodies are unable to reach it. Abnor-
mal -syn finds its way to the cell membrane, where antibod-
ies can recognize it. Although this evidence is really promis-
ing, experimental active immunization, while effective in 
mice, may not be as useful in humans. Indeed, to immunize 
humans in this way by triggering antibody development could 
create harmful inflammation. However, it might be feasible to 
inject antibodies directly, as if the patients were creating their 
own. 
WHO GETS PARKINSON’S DISEASE? REDUCING 
RISK FACTORS 
 PD develops much less frequently than AD, ranging from 
0.1% to 0.5% annually. Depending on the study, the annual 
incidence rate for PD ranges from 110 to 300 per 100.000 
individuals over age 50 [126]. After age 80 years, the inci-
dence rate increases to 400 to 500 individuals per 100.000 
annually. Incidence rates for PD increase with age both in 
men and women, but the rate in men exceeds that for women 
twofold [127]. Among persons over 65 years of age, the 
prevalence of PD has been estimated at 1.8%, increasing 
from 0.6% between ages to 2.6% for those 85-98 years 
[128]. From birth the lifetime risk of developing PD is about 
2% for men and 1.3% for women. These risks increase with 
age [129]. Although idiopathic PD is usually sporadic, it is 
now well established that there is a genetic component to the 
disease [130]. Approximately 5-10% of PD patients have a 
familial form of parkinsonism with an autosomal-dominant 
pattern of inheritance [130]. Case control studies have typi-
cally indicated a 2-14-fold increase in incidence in close 
relatives of PD patients [131] and although concordance 
rates between identical twins are low for overt expression of 
the disease, they are much higher when subclinical decline in 
striatal DAergic dysfunction is measured by positron emis-
sion tomography (PET) imaging (53% in monozygotic twins 
of PD patients, compared with 13% in dizygotic cases [132]. 
The disease was once thought to affect primarily whites, but 
recent studies have demonstrated equal prevalence in African 
Americans and whites living in the same geographic area. To 
date, no studies have determined the prevalence or incidence 
of PD in Hispanics, and retrospective epidemiologic studies 
performed in various major cities have yielded contradictory 
information. Variations in the prevalence of the disease in 
individual racial groups in different geographic areas have 
suggested an increased risk associated with rural living. Pes-
ticides and other toxins have been suspected, but none has 
been proved to be a definite causative factor [133]. It appears 
clear that in PD, the demise of DAergic neurons is induced 
by non-genetic factors such as environmental exposures to 
various toxins, diet and other lifestyle issues, and head in-
jury, probably in interaction with susceptibility genes [134]. 
Premorbid Parkinsonian Personality 
 The hypothesis of a premorbid parkinsonian personality 
has been suggested since the beginning of the last century 
[135]. In view of the fact that the risk factors for PD are un-
clear, the possibility of this distinctive parkinsonian person-
ality is intriguing and of clinical importance. Indeed, if there 
is a personality type in people predisposed to PD, relatively 
simple personality screenings could be used to evaluate indi-
vidual risk for the disease. This assumption has been con-
firmed by successive studies that have shown the existence 
of some personality traits and behaviours that are found in 
those who go on to develop PD [136,137]. This premorbid 
personality consists of traits such as industriousness, punctu-
ality, emotional and attitudinal inflexibility, cautiousness, 
lack of affect and a predisposition to depressive illness [136]. 
These personality characteristics may precede the onset of 
overt clinical
 
symptoms in PD by several years. Thus, pa-
tients with PD show reduced scores on impulsive sensation 
seeking (ISS) inventories [138] and it seems likely that this 
non-engagement in novelty seeking behaviour precedes the 
development of motor abnormalities. Introspective, over-
controlled, anhedonic personality traits together with
 
sup-
pressed aggressiveness are frequently found. In medicated 
and unmedicated PD patients, high harm avoidance has also 
been demonstrated in comparison with healthy controls 
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[139]. In addition, epidemiologic evidence [140] shows that 
there is a low incidence of cigarette smoking, coffee drink-
ing, and alcohol consumption, in people who develop PD, 
again suggesting that there is a behaviour pattern that pre-
dates PD. Therefore, there is the possibility of a neurobi-
ological link between low sensation seeking traits, which 
might underlie the parkinsonian personality, and the hypo-
thetical protective effect of cigarette smoking and caffeine 
consumption on PD. Accordingly, the use of these sub-
stances might be an epiphenomenon
 
rather than being caus-
ally linked. Low sensation seekers may also be more suscep-
tible to environmental
 
toxicants. Shyness is a low ISS trait 
that is found more frequently
 
in first degree relatives of PD 
patients compared with controls and predicts higher reported 
illness rates in response to xenobiotics,
 
such as pesticides 
[141]. In discordant PD monozygotic twins, shyness
 
has 
been found to be more common in the affected sibling [142]. 
 To confirm this evidence, further research is required. 
Even then, the term premorbid is difficult to define due to 
the unknown latent period before onset of PD. Additional 
research would involve correlating personality characteristics 
with activities or changes in the brain. 
Premorbid Health Conditions of PD 
Obesity 
 Dopamine plays important roles in the regulation of food 
intake [143]. Obese persons have lower DA D2 receptor 
availability in the striatum and a body mass index (BMI) 
correlated negatively with the measures of D2 receptors 
[144]. This potential association between obesity and the risk 
of PD has recently been the subject of investigation. Hu et 
al. [145] found in a Finnish population that excess weight, 
defined as a BMI  23, is associated with an elevated risk of 
PD among middle-aged men and women. The evidence that 
being overweight may increase the risk of PD has been con-
firmed in a Japanese population study [146]. Compared to 
the value before the onset of PD, BMI was significantly re-
duced at 2 years after the onset. 
 Even though the mechanism behind the association be-
tween obesity and the risk of PD is poorly understood, sev-
eral factors associated with high BMI can be involved, such 
as lower level of physical activity, dietary factors, etc. 
 Conversely, once the disease is full-blown, PD patients 
exhibit lower body weight when compared to age-matched 
healthy subjects. Possible determinants of weight loss in PD 
patients include hyposmia, impaired hand-mouth coordina-
tion, difficulty chewing, dysphagia, intestinal hypomotility, 
depression, decreased reward processing of DAergic 
mesolimbic regions, nausea, and anorexia as the side effects 
of medication, and increased energy requirements due to 
muscular rigidity and involuntary movements. There is 
enough evidence for recommending monitoring the body 
weight of PD patients as the disease progresses [147]. 
Hypertension, Hypercholesterolemia and Diabetes 
 Hypertension, hypercholesterolemia, and diabetes are 
important risk factors for atherosclerosis [148] and have 
been associated with an increased incidence of stroke, AD, 
and dementia [149,150]. Although the aetiology of PD is 
poorly understood, vascular factors may be influential in 
modulating disease risk. Recently, Ascherio’s group ana-
lysed the association between a history of vascular condi-
tions and risk of PD in two large prospective cohorts [151]. 
Risk of PD was not associated with the history of hyperten-
sion or diabetes. They also found no associations between 
history of use of antihypertensive drugs or cholesterol-
lowering medication and risk of PD. 
 Differently, total cholesterol levels were associated with 
a decreased risk of PD. Analyses stratified by sex revealed a 
modest but significant trend of decreasing PD risk with in-
creasing cholesterol in women but not in men. When ana-
lyzed as a continuous variable, every 50 mg/dL increase in 
total cholesterol was associated with an 18% lower risk of 
PD in women but only a 10% lower risk in men. Men with 
the highest total cholesterol (>270 mg/dL) had a significantly 
lower risk of PD when compared with men with the lowest 
total cholesterol (<159 mg/dL). This evidence should be in-
terpreted with caution because the results are only margin-
ally significant and could have occurred by chance. How-
ever, they are consistent with the lower levels of LDL cho-
lesterol among patients with PD than controls [67] and the 
protective effect against PD of increasing cholesterol ob-
served in women but not in men [68]. Further investigation 
of the potential protective effect of high cholesterol and PD 
is nevertheless warranted (see paragraph on statins). Never-
theless, a history of hypertension [49,50,152] or diabetes 
[152,153] has been associated with a decreased risk of PD. 
In a recent case-control study, a 40% lower risk of PD was 
estimated among subjects with diabetes, and a significant 
interaction between smoking status and diabetes was found 
among men but not women [153]. On the other hand, in a 
cohort study in Finland, risk of PD was 85% higher in men 
and women with type 2 diabetes [154]. 
Uric Acid 
 Uric acid (Fig. 4) is an antioxidant and iron chelator in 
the human body. It has been shown to scavenge hydroxyl 
radicals and peroxynitrate, which are considered to be central 
mediators of oxidative damage in the pathogenesis of PD 
[155,156]. Uric acid can form complexes with iron ions 
[157] and its synthesis seems to be coupled to the production 
of ferritin through a yet unidentified mechanism [158], indi-
cating that both these molecules are involved in sequestering 
free iron in the body. Both ferritin and uric acid levels in the 
SNc of PD brains have been reported to be decreased 
[159,160] and a low level of plasma uric acid and a high 
intake of iron are considered risk factors for the disease 
[161,162]. Plasma uric acid levels are significantly lower in 
PD patients when compared with controls [163]. Interest-
ingly, two prospective population-based cohort studies 
showed that higher serum levels of uric acid were associated 
with a significantly decreased risk of Parkinson’s disease 
(40-30% reduction in PD incidence), with evidence for a 
dose-effect relationship [161,164]. Although the possibility 
that these findings are due to residual confounding or con-
founding by unmeasured factors cannot be completely ruled 
out, these results support the hypothesis that oxidative stress 
is involved in the pathogenesis of PD and that uric acid 
might reduce the risk of PD via antioxidant and iron-
chelating properties. These findings raise the possibility that 
interventions to increase plasma urate may reduce the risk 
and delay PD progression. 
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Fig. (4). (11) Uric acid, 7,9-dihydro-3H-purine-2,6,8-trione. (12) -
tocopherol 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman 
-6-ol. (13) Folate, (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-
yl)methylamino]benzoyl]amino]pentanedioic acid. 
Coenzyme Q10 
 Coenzyme Q10 is used in the treatment of a variety of 
disorders primarily related to suboptimal cellular energy 
metabolism and oxidative injury. CoQ 10 is a component in 
the electron transport system, and operates between, on the 
one hand, two flavin proteins, succinyl dehydrogenase and 
NADH dehydrogenase, and on the other, cytochromes, and 
plays an important role in ATP production during cell respi-
ration (Fig. 1). Immunostaining examination of the autopsied 
brains of sporadic PD patients has shown decreases in mito-
chondrial electron transfer complex I and -ketoglutarate 
dehydrogenase (KGDH) activity [165,166]. Mitochondrial 
respiratory dysfunction can cause oxidative stress, and this in 
turn may cause further mitochondrial respiratory dysfunc-
tion, consequently leading to a vicious cycle, resulting in 
neuronal damage. Beneficial effects of oral CoQ 10 admini-
stration have
 
been found in animal models for PD [167,168] 
and
 
in a multicenter, placebo-controlled, randomized phase II 
trial
 
[70]. Surprisingly, a recent randomized, double-blind, 
placebo-controlled trial failed
 
to show improvement of PD 
symptoms by nanoparticular CoQ 10 and did not meet its 
primary
 
or secondary end points [169]. The levels of CoQ 10 
in PD analyzed in blood samples, failed to find consensus 
between the findings; some studies have reported decreased 
plasma levels, whereas others found no significant changes 
[170,171]. Recently, the concentrations of oxidized CoQ 10 
and reduced CoQ 10 in the cerebrospinal fluid (CSF) of pa-
tients with PD has been examined in order to determine 
whether the balance in oxidized and reduced CoQ 10 is re-
lated to the pathogenesis of PD [172]. The percentage of 
oxidized/total CoQ 10 (%CoQ 10) in the CSF was signifi-
cantly higher in the untreated PD group compared to the 
normal control group. The %CoQ 10 in the CSF of PD pa-
tients showed significant negative correlation with the dura-
tion of illness. These findings in living patients provide in 
vivo evidence for a possible role for %CoQ 10 in the patho-
genesis in the early stages of PD development [172]. 
DIET AND LIFESTYLE 
 Diet may play an important role in the aetiology of neu-
rodegenerative disorders such as AD and PD, by affecting 
the neuronal membrane constitution, altering the oxidative 
balance in the brain
 
or serving as a vehicle for environmental 
neurotoxins. Few
 
epidemiologic studies have been able to 
examine potential associations
 
between diet and PD because 
of the relatively
 
low incidence of the disease and its insidious 
onset. Potential roles of foods and nutrients in determining 
PD risk have been investigated, although the results for more 
of them are still elusive. Elevated risks have been reported 
for higher intakes of total energy, dietary fats, carbohydrate, 
monosaccharide and disaccharide, chocolates and desserts, 
iron, and lutein, and reduced risk for higher intakes of pota-
toes, niacin, and foods containing niacin [173,174]. Most of 
these studies used a retrospective case-control design that is 
not well suited for such investigations because of the poten-
tial for recall and selection biases and because of the diffi-
culty of controlling for the effects that the disease status may 
have on diet. Moreover, intakes of many nutrients are highly 
correlated and specific associations are therefore not always 
easily identified. Only a few population-based prospective 
cohort studies have been done so far. 
 It is well established that consumption of diets rich in 
antioxidant and anti-inflammatory agents, such as those 
found in fruit and vegetables, may lower the risk of PD. New 
evidence suggests that dietary supplementation with fruit or 
vegetable extracts can decrease the age-enhanced vulnerabil-
ity to oxidative stress and inflammation. Thus, nutritional 
intervention may exert therapeutic protection against PD. 
Accordingly, it has been suggested that vegan diets may be 
notably protective with respect to PD [175]. Moreover, a 
caloric restriction diet, a reduction of food intake by 40-60% 
without malnutrition, has recently been shown to protect the 
central DAergic neurons from neurotoxins, at least in part by 
induction of heat-shock proteins [176]. Dietary restriction 
has remarkable benefits for health and lifespan, extending 
the survival of diverse species and can protect against PD 
[177], conceivably, the protection afforded by vegan diets 
reflects a similar mechanism [175]. It is well established that 
exposure of neurons to a mild metabolic stress, can protect 
them against excitotoxicity and other Ca
2+
-mediated neu-
rodegenerative processes. This type of metabolic hormesis 
seems mediated by transcription factors. Exposure of neu-
rons to subtoxic levels of noxious chemicals is increasingly 
recognized as a means of inducing hormesis. This has been 
well established for mitochondrial toxins such as cyanide, 
but may also be a major mode of action of many of the 
health-promoting phytochemicals present in vegetables and 
fruit. Examples include sulforaphane (present at high levels 
in broccoli), curcumin from tumeric root, and resveratrol 
from red grapes [177]. The possibility that vegan diets could 
be therapeutically beneficial in PD, by slowing the loss of 
surviving DAergic neurons, thus retarding progression of the 
syndrome, may merit examination. Vegan diets could also be 
helpful to PD patients by promoting vascular health and aid-
ing the blood-brain barrier transport of L-dopa [175]. The 
overall evidence from these studies appears to support a 
healthy unbalance of calorie intake and output, preferring a 
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reduction of food intake; this may be better interpreted as 
maintaining a healthy weight rather than severely restricting 
calories. 
Macronutrients 
Fat and Fatty Acids 
 Evidence from several research areas underlines the im-
portance of unsaturated fatty acids for neuronal cell function. 
The relation between dietary fat and PD is unclear. Diets 
with high lipid content could theoretically increase the 
amount of oxygen radicals by lipid peroxidation and thus 
increase the risk of PD [178]. On the contrary, a significant 
inverse association between total fat intake and PD risk has 
been reported [64], emphasizing the selective role of unsatu-
rated fatty acids in lowering the risk of PD. In this prospec-
tive population-based cohort study intakes of total fat, 
monounsaturated fatty acids (MUFAs), and polyunsaturated 
fatty acids (PUFAs) were significantly associated with a 
lower risk of PD. They observed an association for omega3-
PUFA intake seemed to be driven by the subtype of -
linolenic acid, which makes up 88% of all omega3-PUFA 
intake. Linoleic acid accounts for 99% of all omega6-PUFA 
intake and drove the association for total omega6-PUFA. 
Intakes of other subtypes were very low and not related to 
the risk of PD. An inverse association of total fat intake with 
PD risk was found which was very similar to the one for cis-
unsaturated fatty acids (MUFA and PUFA together). This 
association may have been partly driven by the association 
between cis-unsaturated fatty acids and PD, as more than 
half of total fat intake consists of cis-unsaturated fatty acids. 
Indeed, a trend for an inverse association between saturated 
fatty acids and cholesterol and the risk of PD has also been 
reported. There are several reasons why dietary intake of 
unsaturated fatty acids might influence the risk of neurode-
generative diseases and in particular PD. First, PUFAs have 
anti-inflammatory and neuroprotective properties [179] and 
MUFAs are thought to reduce oxidative stress [180]. Second, 
the fatty acid composition of cell membranes is affected by 
diet [181]. Third, PUFAs are precursors for endogenous can-
nabinoids, which play a role in the control of movement by 
modulating DAergic activity in the basal ganglia [182]. Fi-
nally, evidence is increasing that lipids may also regulate -
syn aggregation, the major component of the inclusion bod-
ies found in the brains of patients with PD [183]. Few studies 
focused on unsaturated fat in relation to PD. Within the 
Honolulu-Asia Aging Study, a significantly reduced risk of 
PD observed with higher intake of PUFAs [184] was only 
partially confirmed in the Health Professionals Follow-Up 
Study and the Nurses’ Health Study [68]. Of the several 
PUFA subtypes, only arachidonic acid was significantly as-
sociated with a lower PD risk. However, isocaloric replace-
ment of polyunsaturated fat with saturated fat was associated 
with a significantly increased risk of PD in the men [68]. 
Dairy Food Consumption and Risk of Parkinson's Disease 
 Recently [185-187], the association between intake of 
dairy products and risk of PD has been investigated. Higher 
consumption
 
of dairy products was associated with increased 
risk of PD. The association was stronger in men and was 
mostly
 
explained by milk consumption [187]. Men in the 
highest quintile of intakes of dairy products had a 50 to 80% 
increase in PD risk compared with men in the lowest quintile 
[187]. Men who consumed more than 16 ounces (0.5
 
liters) 
of milk per day had a 130% higher risk of PD than men who 
did not drink milk [186]. The effect of milk consumption on 
PD seems also independent of the intake of Ca
2+
. However, 
dairy intake was not associated with PD risk in women, and 
no other food groups were associated with PD risk in either 
men or women. Among men, PD risk increased significantly 
with greater intakes of cream cheese, other cheese, and sour 
cream, and marginally with skim or low fat milk intake. In 
addition, PD risk was not significantly associated with intake 
of dairy fat or animal fat, but rather with intakes of nonfat 
constituents of dairy foods in men. Moreover, there was a 
lack of association between PD risk and calcium, vitamin D, 
and protein from nondairy foods or supplements, suggesting 
that intake of these nutrients is not causally related to PD 
risk [187]. The exact cause of is not clear; however, the 
process may include oxidative stress and mitochondrial dys-
function. There is no apparent evidence linking intake of 
milk or its components to DAergic neuron death in PD. Re-
peated oral infusions of milk decreased extracellular DA 
concentrations in newborn rats [188] but no information on 
the effects of milk consumption in adult animals has been 
reported. Neither the presence of some unmeasured compo-
nents nor contamination of dairy with pesticides or poly-
chlorinated biphenyls can be excluded. The fact that a simi-
lar association was not present in women requires caution in 
interpreting the results. Future epidemiologic and experi-
mental investigations
 
are needed to further evaluate this as-
sociation and to ascertain
 
the underlying mechanisms. 
Micronutrients 
Vitamins 
 Antioxidants such as vitamin C (ascorbic acid), vitamin E 
(-tocopherol) (Fig. 4), and carotenoids such as  carotene 
are thought to protect cells from oxidative injury [189]. A 
recent meta-analysis [190] showed that a moderate intake of 
vitamin E seemed to decrease the risk of developing PD by 
20%, suggesting that foods rich in vitamin E may be protec-
tive. This protective influence was seen with both moderate 
intake and high intake of vitamin E, although the possible 
benefit associated with high intake of vitamin E was not sig-
nificant. The risk of PD, however, is significantly reduced 
among men and women with high intake of dietary vitamin 
E (from foods only) [91]. Consumption of nuts is also sig-
nificantly associated with a reduced risk of PD. Neither vi-
tamin C nor  carotene seems to have a neuroprotective ef-
fect. Given that these data are observational, confirmation 
from well-designed randomised controlled trials is necessary 
before suggesting changes in routine clinical practice. 
 Vitamin B complex has been studied as well. Vitamin B6 
is required to convert homocysteine to cysteine, which in 
turn is the rate-limiting precursor in the synthesis of glu-
tathione [191]. Reduced levels of glutathione, a major anti-
oxidant, have been found in DAergic neurons of PD patients 
[192]. Consequently, higher intakes of folate (Fig. 4) and 
vitamins B12 and B6 might decrease the risk of PD by de-
creasing homocysteine levels which might enhance DAergic 
cell death through neurotoxic effects. This hypothesis has 
been corroborated by a recent publication of the Rotterdam 
Study group showing that dietary vitamin B6 was associated 
with a lower risk of PD with evidence for a dose-effect rela-
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tionship [193]. In addition, stratified analyses revealed that 
this association was restricted to smokers, probably ac-
counted for by mutually reinforcing beneficial effects of 
smoking and vitamin B6 intake on the risk of PD. Con-
versely, no significant association with PD risk was observed 
for folate and vitamin B12, although their potential effect on 
PD risk is not completely ruled out [193]. Several lines of 
evidence suggest neuroprotective properties of vitamin B6 
through antioxidant capacities, in addition to decreasing 
plasma homocysteine [194]. Because oxidative stress may be 
prominent in PD pathogenesis, higher vitamin B6 intake may 
thus reduce PD risk through antioxidant effects. 
Minerals 
Dietary Iron 
 Analysis of iron in the brain of PD patients has shown a 
selective and increased level of iron in the SNc [195]. If iron 
is freed from binding to neuromelanin or ferritin, hydroxyl 
radicals produced by Fenton reaction might induce DAergic 
neurons’ death. Thus, it is plausible that selective increase of 
iron in the melanized SNc DAergic neurons, possibly due to 
excessive dietary intake and impaired iron metabolism, could 
lead to progressive degeneration of these neurons. Two case-
control studies found a positive association between iron 
intake and PD [63,162]. Powers and colleagues [63] per-
formed analyses of dietary iron intake stratified on intake of 
multivitamins or iron supplements, and observed a moderate 
association between iron intake from foods and PD. The 
added increase in risk from iron in food plus iron from mul-
tivitamins and iron supplements supports the hypothesis that 
total iron intake is a potential risk factor for PD. Moreover, 
these authors showed a consistent moderately elevated risk 
for high manganese intake as well. Of paramount importance 
is the evidence that an increased intake of iron plus manga-
nese could accentuate (nearly twofold increase) the risk of 
PD by either metal alone. There are foods in common link-
ing these two elements as potential risk factors, such as spin-
ach, lima beans, peas, wheat bread, peanuts, and other nuts 
and seeds. Multivitamins also contain manganese; thus, the 
added risk may be partly due to the joint effect of iron and 
manganese. These findings are not in agreement with former 
evidence that failed to show any association between iron 
intake and risk of PD [196,173]. Further studies on the rela-
tion between dietary iron and the risk of PD are consequently 
warranted. 
Selenium 
 Selenium is very important in the cellullar control of 
oxyradicals. The dietary significance of selenium was clari-
fied by the demonstration that it was a component of the 
detoxifying enzyme seleno-glutathione peroxidase (GPx) 
[197]. Many DAergic neurons of the SNc express low levels 
of GPx antigen, in contrast to the VTA [198]. Nutritional 
deficiency in selenium is accompanied by a decrease in the 
activity of GPx [199]. Although selenium deficiency occurs 
rarely, it may be produced by a change in the diet during 
short periods of malnutrition which are not rare during aging 
due to a decrease in appetite and the loss of taste capacity. A 
selenium-deficient diet for a short period of time decreases 
brain protection, principally in the SNc, against oxidative 
damage [200]. Incongruously, selenium increases in CSF of 
PD patients [201]. Dietary selenium and risk of PD has not 
been studied so far. 
Dietary Supply of Antioxidants 
 Although antioxidants and supplements theoretically 
could help
 
in the treatment of PD, the clinical data support-
ing their role
 
are marginal. It is possible that dietary intake of 
foods high
 
in antioxidants may reduce risk of developing PD. 
Although the available data are still limited, epidemiological 
studies indicate that dietary antioxidants influence the inci-
dence of neurodegenerative disorders such as dementia (in-
cluding AD) and PD [201-205]. For example, incidence data 
from the so-called PAQUID (Personnes Agees Quid) study 
showed that people drinking 3-4 glasses of wine per day had 
an 80% decreased incidence of dementia and AD 3 years 
later, compared to those who drank less or did not drink at 
all [203-205]. These protective effects are most likely due to 
the presence of antioxidants in food and beverages inasmuch 
as it has been found that wine drinking and the consumption 
of other foods and drinks which are rich in polyphenols can 
increase the antioxidant activity in serum [204]. More re-
cently, investigators in the Rotterdam Study [206] reported 
that any form of moderate alcohol would have the same 
beneficial effects. The risk reduction associated with alcohol 
is possibly related to its antioxidant properties or its effects 
on lipid metabolism. The clinical findings indicating a pro-
tective effect of dietary flavonoids against neurodegenerative 
diseases are supported by data obtained in laboratory animals 
showing that dietary supplementation containing fruit and 
vegetables rich in antioxidants (blueberries, strawberries and 
spinach) can have beneficial effects on age-related decline of 
neuronal and cognitive functions in old rats [207]. Several 
thousands molecules having a polyphenolic structure have 
been identified in higher plants and are generally involved in 
defence against ultraviolet radiation or aggression by patho-
gens [208]. More than 4000 varieties of flavonoids have 
been identified, many of which are responsible for the attrac-
tive colours of flowers, fruits, and leaves. Flavonoids repre-
sent the single, most widely occurring group of phenolic 
phytochemicals [209]. In recent years, there has been an in-
creasing interest in investigating the many positive pharma-
cological properties of flavonoids. Much of this interest has 
been spurred by the dietary anomaly referred to as the 
“French paradox”, the apparent compatibility of a high satu-
rated fat diet with a low incidence of coronary atherosclero-
sis [210]. Epidemiological studies have shown that moderate 
wine consumption can be protective against neurological 
disorders such as age-related macular degeneration [211]. 
Moreover, in vitro and in vivo pre-clinical studies have 
shown the neuroprotective effect of lyophilized red wine 
[212], grape polyphenols [213], quercetin [214], trans-
resveratrol [212,215,216], and (+)-catechin [217]. There is 
also increasing interest for the role of tea (Camellia sinensis) 
in maintaining health and in treating disease. Despite the 
high consumption of tobacco, Asia and Japan in particular 
have among the lowest incidences of arteriosclerosis and 
lung cancer per capita. It has been postulated that this para-
dox, this time referred to as the “Asian Paradox”, exists as a 
result of the high consumption of green tea in this region, 
and most benefits occur when approximately 1.2 L of green 
tea are consumed every day. Although tea consists of several 
components, research has focused on polyphenols, especially 
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those found in the unfermented tea leaves, known as green 
tea. The green tea polyphenols include (-)-epicatechin (EC), 
(-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), 
(-)-epigallocatechin-3-gallate (EGCG) (Fig. 5). Of these, 
EGCG generally accounts for greater than 40% of the total 
[218]. Green tea polyphenols are potent antioxidants [219]. 
EGCG usually has the greatest antioxidant activity, and is 
the most widely studied polyphenol for disease prevention 
[218,210]. Many of the putative health benefits of tea are 
presumed to be a result of its antioxidant effects. 
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Fig. (5). (14) (-)-epigallocatechin-3-gallate (EGCG), [(2R,3R)-5,7-
dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydro-
xybenzoate. (15) Nicotine, 3-(1-methylpyrrolidin-2-yl)pyridine. 
(16) Caffeine, 1,3,7-trimethylpurine-2,6-dione. 
 The epidemiological evidence indicating the putative role 
of nutritional antioxidants in the prevention and attenuation 
of neurodegenerative disorders is receiving experimental 
confirmation in a number of laboratory studies [218,220, 
221]. 
 Moreover, recent reports have revealed that flavonoids 
may be neuroprotective in neuronal primary cell cultures. 
For example, the Ginkgo biloba extract, known to be en-
riched with flavonoids, has been shown to protect hippo-
campal neurons from NO or -amyloid derived peptide-
induced neurotoxicity [222,223]. In addition, the extract of 
Ginkgo biloba referrred to as Egb 761 is one of the most 
popular plant extracts used in Europe to alleviate symptoms 
associated with a range of cognitive disorders [224]. The 
mechanism of action of Egb 761 in the CNS is only partially 
understood, but the main effects seem to be related to its 
antioxidant properties, which require the synergistic action 
of the flavonoids, the terpenoids (ginkgolides, bilobalide), 
and the organic acids, principal constituents of Egb [225]. 
These compounds to varying degrees act as scavengers of 
ROS, which have been considered the mediators of the ex-
cessive lipid peroxidation and cell damage observed in PD 
[226]. 
 In summary, the bulk of recently published data illus-
trated the emerging and promising role of polyphenolic 
compounds as therapeutic tools in PD. Many studies high-
lighted that polyphenols could protect neurons against vari-
ous toxic compounds. The emerging view is that polypheno-
lic compounds could exert beneficial effects on cells not 
only through their antioxidant potential but also through the 
modulation of different pathways such as signalling cas-
cades, anti-apoptotic processes. Moreover, different path-
ways could be activated by different polyphenols present in 
the same extracts with benefical interactions or synergistic 
effects. Elucidation of their mechanism of action should pro-
vide new insight for new targets for neuroprotective drugs. 
The studies described above demonstrate that the concentra-
tions of polyphenols from diet are high enough in vivo to 
display pharmacological activity in the brain. Furthermore, 
polyphenol supplements such as green tea polyphenols or 
catechins, ginseng, ginkgo biloba and EGb 761, polygonum, 
triptolide, might have potential clinical benefit in prevention 
of PD in humans [226]. 
Tobacco, Coffee, and Alcohol 
Smoking 
 An inverse association between cigarette smoking and 
PD has been consistently confirmed by different epidemiol-
ogical studies [227-229]. It seems clear that a protective, 
dose-dependent role for cigarette
 
smoking and potentially 
other types of tobacco use on PD risk exists. Importantly, 
estimated effects seem unaltered by sex or education
 
but are 
stronger among those with younger age of disease onset 
[227]. Nevertheless,
 
only randomized intervention trials can 
confirm that some components
 
in tobacco are truly neuropro-
tective, negating the possibility
 
that a premorbid personality 
influences smoking behaviour among
 
those who later de-
velop PD. The biological basis that might underlie smoking 
effects is still poorly understood. Several mechanisms have 
been proposed to explain the potential neuroprotective effect 
of cigarette smoking. The most likely explanation for this 
effect is due to the nicotine in tobacco (Fig. 5). Nicotine in-
teracts with multiple nicotinic receptor (nAChR) subtypes in 
the peripheral and central nervous system, as well as in 
skeletal muscle. Recent results show that striatal 62-
containing nAChRs are particularly susceptible to nigrostri-
atal damage, with a decline in receptor levels that closely 
parallels losses in striatal DA. These observations suggest 
that development of nAChR agonists or antagonists targeted 
to 62-containing nAChRs may represent a particularly 
relevant target for PD therapeutics [230,231]. Although a 
major focus is on receptor-mediated protection, nicotine 
might play also a more direct role bypassing nACh receptors. 
Indeed, new evidence shows that nicotine can act as a neuro-
protectant via an anti-inflammatory mechanism mediated by 
the modulation of microglial activation [232]. Along with 
various nicotine effects, this anti-inflammatory mechanism 
could have a major therapeutic implication in the preventive 
treatment of PD. It is evident that the observation of a re-
duced PD risk in smokers needs cautious interpretation as it 
might result from bias due to selective mortality of smokers 
among people without PD, inaccurate recording of PD diag-
noses in smokers, and confounding by unknown factors. 
Coffee and Tea Consumption 
 The adverse effects of cigarette smoking on health
 
and 
the difficulty in determining whether nicotine or other
 
to-
bacco chemicals may be potentially beneficial in preventing
 
PD have tempered the enthusiasm for pursuing
 
the investiga-
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tion of the potential neuroprotective effects of
 
tobacco. In 
contrast, the identification of caffeine (Fig. 5) as the
 
explana-
tory molecule for the reduced risk of PD in coffee drinkers 
appears more promising. Indeed, numerous studies have de-
scribed associations for caffeine consumption in relation to 
PD risk indicating that caffeine consumers are significantly 
less likely to develop PD than those never exposed [229]. 
Caffeine is generally thought to be the active component, 
given that total caffeine intake and intake of caffeine from 
non-coffee sources were found to be inversely related to PD 
risk, whereas no association was seen between other compo-
nents in coffee and the risk of PD [233]. Experimental evi-
dence suggests that caffeine has potential antiparkinsonian 
properties, as demonstrated by its protective effects against 
toxins [234,235]. Caffeine is an antagonist at the A1 and A2A 
subtypes of adenosine receptors, and selective drugs for 
these receptors have been proposed for PD therapy [236]. 
The epidemiological studies have shown that the inverse 
association between coffee and PD is strong and significant 
only in men, whereas in women it is weaker and only mar-
ginally significant [233,237]. The explanation for this con-
trasting gender differences might depend on oestrogen effect 
on caffeine metabolism. In fact, oestrogen, which can serve 
as
 
a neuroprotectant in its own right, interferes with neuro-
protection
 
by caffeine against nigral DAergic degeneration 
[238]. Furthermore, this gender difference disappears when 
men are compared to those women who had never used
 
oes-
trogen replacement therapy but not those who had used
 
it 
[239,240]. This evidence suggests that
 
oestrogen replacement 
therapy may prevent the beneficial effect
 
of caffeine in re-
ducing the risk of developing PD. A better understanding of
 
the interplay between environmental factors like caffeine and
 
oestrogen may suggest effective preventative as well as 
therapeutic
 
strategies for this neurodegenerative disorder. 
Recently, green tea has attracted great attention particularly 
with respect to its potential for preventing and treating can-
cer, cardiovascular or inflammatory diseases [241]. Con-
sumption of tea seems to have beneficial role in reducing 
risk of PD as well [242,243]. The consumption of the num-
ber of cup-years of tea is inversely correlated with risk of 
PD. One unit of tea (3 cups/day for 10 years) would lead to 
28% risk reduction of PD [243]. The tea beneficial role is 
likely depending on flavonoids (30% of the dry weight of a 
leaf) including catechins and their derivatives rather than 
caffeine that is also present in tea. Hence, the polyphenol 
epicatechin was shown to attenuate neurotoxicity induced by 
oxidized low-density lipoprotein in mouse-derived striatal 
neurons [220]. Thus a pretreatment of mice with either green 
tea or EGCG prevented DAergic neurons in the nigro-striatal 
pathway induced by MPTP [218]. Tea extracts and EGCG 
attenuated the neurotoxic action of 6-hydroxydopamine (6-
OHDA) in rat PC12 cells and human neuroblastoma SH-
SY5Y cells [221]. EGCG exerts potent DAergic neuropro-
tective activity by means of microglial inhibition [244]. In 
addition, the neuroprotective effect of EGCG may involve its 
catechol structure, its free radical scavenging and metal 
chelator (especially iron) properties [245]. Although a nega-
tive association between cigarette smoking, tea or coffee 
drinking with the occurrence of PD is well documented, un-
fortunately these factors do not have a disease modifying 
effect in already diagnosed PD [246]. 
 
Alcohol Consumption 
 It has been reported that the risk of PD is significantly 
lower in drinkers of 2+ alcoholic drinks/day compared to 
abstainers; this applied to both wine and liquor drinkers 
[50,247,248]. However, this protective effect has not been 
confirmed in other studies [249,250]. There is enough ex-
perimental evidence [212-217] that red wine consumption 
may be beneficial in the prevention of age-related neurode-
generative disorders such as PD.  
CONCLUDING REMARKS 
 Based on the epidemiological evidence reviewed so far, 
numerous factors seem to predispose certain individuals to 
develop PD. Furthermore, a variety of acquired factors, such 
as exposure to well water, herbicides, industrial chemicals, 
wood pulp mills, farming, and living in a rural environment 
may contribute to disease pathogenesis. A number of exoge-
nous toxins have been associated with the development of 
parkinsonism, including trace metals, cyanide, lacquer thin-
ner, organic solvents, carbon monoxide, and carbon disulfide 
[130]. 
 Prevention strategies can be developed only if the risk 
and protective factors for PD are known. Older age and 
smoking habits are the only risk factors for PD that have 
consistently been found across studies so far. For most of the 
factors, evidence remains uncertain and not fully understood. 
For example in the recent positive association found between 
fatherhood and PD [251], where surprisingly the risk seems 
to increase with increasing number of children. 
 We are far away from knowing with clarity all the risk 
factors of PD. Epidemiology will help and some methods 
will become more sophisticated, but the basic principles of 
minimizing the role of chance, bias, and confounding will 
remain. Indeed, initial studies were too small or had meth-
odological limitations that hampered the interpretability of 
their findings. Large, well-designed, prospective population-
based cohort studies are the only studies suited to examine 
the effects of multiple potential risk factors and their interac-
tions, as well as effects that develop over a longer period. In 
the coming years, and possibly through pooling of studies to 
further increase statistical power, we will gain a better in-
sight into the role of environmental factors in the pathogene-
sis of this devastating disease. Based on current knowledge 
of risk and protective factors, prevention strategies for those 
who have no clinical symptoms of PD, and those who are at 
high risk of developing these neurological disorders can be 
proposed. Collectively, the available data suggest that a 
brain-healthy diet is very similar to a heart-healthy diet. This 
involves a balanced low-calorie diet that contains unsatu-
rated fat and plenty of fruit and vegetables rich in antioxi-
dants. Although antioxidants should derive essentially from 
fresh food, vitamin E supplementation is recommended. 
Moreover, regular consumption of a variety of juices (200 ml 
per day), namely, purple grape juice, which contains the 
highest levels of flavan-3-ols and procyanidins, anthocyan-
ins, and hydroxycinnamates, a flavonol-rich cranberry juice 
drink, grapefruit juice, which contains flavanones in high 
levels, and cloudy apple juice, which is a good source of 
hydroxychalcones and flavan-3-ols should be part of the 
meal [252]. Overall, it is of paramount importance to main-
tain brain antioxidants at levels that are higher than normally 
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provided by nature and a high dietary intake may be indi-
cated from childhood. 
 Moreover, life modifications should begin early and 
should include daily moderate exercise, reduced stress and 
no tobacco smoking (nicotine’s neuroprotective effect should 
be obtained by other drug preparations), drinking coffee, 
green tea and moderate intake of alcohol especially red wine, 
avoiding exposure to pesticides and intake of iron and Mn 
through supplements. 
 Unfortunately, a strong rationale does not exist instead 
for the use of statins, CCBs or NSAIDs in primary preven-
tion of PD. On the other hand, the vaccine development and 
other immunotherapies against PD that would provide bene-
fits to people who are not diagnosed with PD seem far away. 
 In conclusion, we do not know if PD will be prevented, 
without doubt we can reduce the risk so far known. 
ACKNOWLEDGEMENT 
 We thank Dr. Clare Austen for the proofreading of the 
manuscript. 
ABBREVIATIONS 
%CoQ 10 = Oxidized/total CoQ 10 
.
OH = Hydroxyl radicals 
6-OHDA = 6-Hydroxydopamine 
AD = Alzheimer disease 
AP-1 = Activator protein 1 
APOE = Apolipoprotein 
BMI = Body mass index 
Ca
2+
 = Calcium ions 
cAMP = Cyclic adenosine monophosphate 
CCBs = Ca
2+
 channel blockers 
CNS = Central nervous system 
CoQ 10 = Coenzyme Q10 
COX-2 = Cyclooxygenase-2 
CSF = Cerebrospinal fluid 
DA = Dopamine 
DAergic = Dopaminergic 
EC = (-)-Epicatechin 
ECG = (-)-Epicatechin-3-gallate 
EGC = (-)-Epigallocatechin () 
EGCG = (-)-Epigallocatechin-3-gallate 
GDNF = Glial-derived neurotrophic factor 
HCN = Hyperpolarization-activated cyclic nucleo-
tide-gated cation 
HMG-CoA = 3-Hydroxy-3-methylglutaryl coenzyme A 
h-syn = Human -syn 
IFN-  = Interferon  
IL-1 = Interleukin-1 
IL-6 = Interleukin-6 
iNOS = Inducible NO synthase 
ISS = Impulsive sensation seeking 
LDL = Low-density lipoprotein 
LDL-C = LDL cholesterol 
LTs = Leucotriens 
MAOS = Membrane associated oxidative stress 
MPTP = 1,2,3,6-Tetrahydropyridine 
MS = Multiple sclerosis 
MUFAs = Monounsaturated fatty acids 
NAA = N-acetylaspartate 
nAChR = Nicotinic receptor 
NF-B = Nuclear factor-kappa B 
NO = Nitric oxide 
NSAIDs = Nonsteroidal anti-inflammatory drugs 
VGCC = Voltage-Gated Calcium Channel 
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